HORMA domain-containing protein 2 (HORMAD2)

HORMA domain-containing protein 2 (HORMAD2) is a highly conserved, meiosis-specific structural regulatory protein containing a characteristic HORMA domain, named after its homologues Hop1, Rev7, and Mad2[1][2]. In mammals, including humans and mice, HORMAD2 localizes to unsynapsed axes of meiotic chromosomes during prophase I, where it plays crucial roles in the formation of the synaptonemal complex, regulation of meiotic recombination, and the checkpoint mechanisms that eliminate defective gametes[2][1]. HORMAD2 acts as a scaffold for the recruitment of ATR kinase to regions of chromosome asynapsis, thus aiding in the surveillance for unpaired chromosomes and contributing to quality control in gamete development[2]. Removal of HORMAD2 from synapsed chromosomes is tightly controlled by the AAA+ ATPase TRIP13, which remodels the N-terminal flexible region of HORMAD2 for dissociation from the synaptonemal complex[2]. Mutations in HORMAD2 can disrupt fertility, typically through effects on meiosis and gametogenesis, but HORMAD2 is not currently a therapeutic drug target, has no known small-molecule inhibitors, and is not directly associated with major human diseases outside reproductive biology[2]. Key Points: - HORMAD2 is *not* a classic therapeutic target such as a receptor, enzyme, transporter, or ion channel. - Its primary function is in meiotic chromosome dynamics and surveillance, with well-established roles in fertility but no current links to direct disease targeting or approved drugs[2]. - There are no reported drugs, approved mechanisms of action for modulation, or established biomarkers involving HORMAD2 for patient selection or monitoring as of current knowledge. - HORMAD2’s dysfunction is mainly associated with abnormal gametogenesis and infertility, not with major systemic disease or safety concerns[2].

Other names

HORMAD2MGC26710CT46.2HORMA domain containing 2